Monitoring Agency Report for the Quarter ended on March 31, 2026.
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CRISIL Ratings Limited, the monitoring agency for Anlon Healthcare's IPO, submitted its Q4 FY2026 report. The IPO raised Rs 12,103 lakh (net proceeds Rs 10,589.95 lakh) in August 2025. The company has fully deployed funds for manufacturing expansion (Rs 3,071.95 lakh), debt repayment (Rs 500 lakh), and working capital (Rs 4,315 lakh). Notably, the company made two acquisitions using IPO proceeds: Bizotic Life Science Private Limited for Rs 379.69 lakh and Apiqo Organics Private Limited for Rs 540.06 lakh. These acquisitions were part of an expanded scope approved by shareholders on January 7, 2026, which added inorganic growth to the original expansion object. Issue expenses came in Rs 84.39 lakh lower than estimated, and this was reallocated to General Corporate Purposes. Only Rs 13.20 lakh remains unutilized in the Public Issue Account.
The utilization of IPO proceeds is largely on track with appropriate approvals obtained for deviations. The inorganic acquisitions demonstrate the company is executing its growth strategy post-IPO, which could be positive for long-term value creation.